Analyzing Endologix (ELGX) and Its Peers

Endologix (NASDAQ: ELGX) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Endologix to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, institutional ownership and profitability.

Volatility and Risk

Endologix has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Endologix’s competitors have a beta of 0.21, indicating that their average share price is 79% less volatile than the S&P 500.

Insider & Institutional Ownership

54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 3.9% of Endologix shares are held by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Endologix and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -41.60% -52.18% -13.70%
Endologix Competitors -101.23% -92.70% -30.32%

Analyst Recommendations

This is a breakdown of current recommendations for Endologix and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 7 1 0 2.13
Endologix Competitors 112 734 1029 10 2.50

Endologix presently has a consensus target price of $5.36, indicating a potential upside of 6.50%. As a group, “Medical Devices & Implants” companies have a potential upside of 38.86%. Given Endologix’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Endologix has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Endologix and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Endologix $192.93 million -$154.67 million -5.41
Endologix Competitors $1.67 billion $207.58 million 68.42

Endologix’s competitors have higher revenue and earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Endologix competitors beat Endologix on 9 of the 13 factors compared.

Endologix Company Profile

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

What are top analysts saying about Endologix? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endologix and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit